Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo

Blood. 2004 Mar 1;103(5):1966-7; author reply 1967. doi: 10.1182/blood-2003-10-3475.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antigens, CD34 / biosynthesis
  • Antineoplastic Agents / pharmacology
  • Benzamides
  • Cell Differentiation
  • Cell Line, Tumor
  • Dendritic Cells / cytology*
  • Dendritic Cells / drug effects*
  • Dendritic Cells / metabolism
  • Granulocyte-Macrophage Colony-Stimulating Factor / metabolism
  • Humans
  • Imatinib Mesylate
  • Immunotherapy / methods
  • Interleukin-4 / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Membrane Proteins / metabolism*
  • Piperazines / pharmacology*
  • Pyrimidines / pharmacology*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antigens, CD34
  • Antineoplastic Agents
  • Benzamides
  • Membrane Proteins
  • Piperazines
  • Pyrimidines
  • Tumor Necrosis Factor-alpha
  • flt3 ligand protein
  • Interleukin-4
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Imatinib Mesylate